Ribociclib is an inhibitor of cyclin D1/Cyclin-dependent kinase 4(CDK4) and Cell division protein kinase 6 (CDK6). Ribociclib is used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor indicated in combination with an aromatase inhibitor which is used for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. Various Ribociclib related compounds or reference standards, listed on this page are needed in pharmaceutical research at the time to product development, ANDA filing or during production to study quality, stability, and genotoxicity study of Ribociclib related products.


Synthink is a most trusted source of Ribociclib Degradation Impurities, Ribociclib Genotoxic impurity, Ribociclib Process Impurities, USP related compounds, Ribociclib Nitrosamine impurity, N-Nitroso impurity etc. which are listed on this page.